To receive POXEL information in real time, send a request to [email protected]
LYON, France, May 4, 2022 – POXEL SA (Euronext: POXEL – FR0012432516), a clinical-stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic diseases , announces today that it has filed with the Autorité des Marchés Financiers (AMF) its Universal Registration Document for the financial year ended December 31, 2021.
This document is available on the AMF’s website (in English) and on Poxel’s website (www.poxelpharma.com), in the Investors/Shareholder-Information/Regulatory-Information section (in French and English).
The 2021 Universal Registration Document includes:
• the 2021 Annual Financial Report, including the Management Report, and
• the Corporate Governance Report.
This year, the Company’s Universal Registration Document includes a new Corporate Social Responsibility (CSR) report, which reflects the Company’s 2021 review and assessment of its existing corporate social responsibility actions. companies (CSR). It also describes Poxel’s CSR strategy. Poxel’s CSR report will be available on the Company’s website, in the Investors / Corporate Governance section.